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Polycystic ovarian syndrome is one of the commonest endocrinopathies in women of 
reproductive age.   The prevalence of the disease is estimated to be around 5 % in 
general population (Azziz, 2004).  Literature on the prevalence of PCOS in Black 
women is limited (Knochenhauer, 1998).  This syndrome is a diagnostic conundrum 
due to the phenotypic variability of these women.  The PCOS woman also has a 
greater disposition for impaired glucose homeostasis as well as hyperlipidaemia.   
 
OBJECTIVE 
The hormonal and metabolic profiles of South African women with PCOS have not 
been described. Ethnic differences in the prevalence of PCOS have also not been 
well explored. Our study aims to describe and compare the phenotypic profile of 
African and Indian women with PCOS and to determine the frequency of insulin 
resistance and hyperlipidaemia in these women. 
 
METHODS 
A retrospective audit of all patients attending gynaecology endocrine and infertility 
clinics over the period June 2005 to June 2009 was carried out. The biochemical and 
clinical profiles were analysed and a comparative analysis between the two largest 
groups, Indian and Black women were done. All women that attended these clinics 
were subjected to a fasting lipogram and fasting serum glucose.  An abnormal 






A total of 110 patients were analysed in this study.  There were 87 Indian patients, 
16 Black patients, 5 Coloured patients and 2 White patients. Eighty nine percent of 
PCOS women studied had an increased body mass index (>25).  There was an 
increased LH:FSH in 66 (75.9%) of Indian women and 13 (81.3%) of Black women.  
Increased androgens were present in 26 (30.2%) in Indian women and 6 (37.5%) of 
Black women.  An increase in fasting insulin was found in 48 (55.2%) of the Indian 
women and 5 (31.3%) of the Black women.  Twenty five (29.1%) Indian women had 
an increase in fasting serum glucose compared to 1 (6.3%) in Black women.  In the 
Indian population, 13(14.9%) were found to have Diabetes Mellitus, and 9 (10.3%) 
had an impaired glucose tolerance test. In the Black population only 1 patient had 
impaired glucose tolerance.  There were no Black patients with Diabetes Mellitus. No 
Black women were found to have hyperlipidaemia, however 12 (14.3%) Indian 
women were affected.  None of these differences between the races were 
statistically significant.  The major limitation of the study was the sample size of 
Black women.  This is an ongoing study, and aims to recruit more Black women.  
This will be able to adequately address the correct perspective regarding the 











The prevalence of insulin resistance and hyperlipidaemia in local women with PCOS 
was 50.9%.and 11.3% respectively. Menstrual irregularities and infertility are the 
most frequent presenting complaints of women with PCOS.  Features of 
hyperandrogenism are not common presenting complaints in South African women.  
There are no differences in the hormonal and clinical profile of South African Indian 
and Black women with PCOS, however, there is a trend toward Indian women 
having a greater prevalence of glucose abnormalities than Black women.  We 
recommend further studies in the management of the metabolic abnormalities in 
local women with PCOS, in an attempt to develop a protocol to manage the 
































Polycystic ovarian syndrome (PCOS) is one of the commonest endocrinopathies in 
women of reproductive age.   The prevalence of the disease is estimated to be 
around 5 % in the general population (Azziz et al, 2004). 
 
The exact aetiology of PCOS remains a conundrum. A genetic association has been 
suggested, however, the gene or genes responsible are yet to be discovered 
(Kahsar-Miller et al, 2001).  Other theories suggest androgen overexposure in the 
prenatal period (Xita et al, 2002). The exact mechanism of this excessive androgen 
exposure resulting in PCOS, as yet, remains undefined.  A strong familial link has 
also been noted (Balen et al, 2004). An estimated fifty per cent of first degree 
relatives have PCOS suggesting a dominant pattern of inheritance. 
 
Women with PCOS have a variety of clinical presentations.  These range from 
increased weight gain, dysfunctional uterine bleeding, oligo/amenorrhea, acne, 
hirsuitism, acanthosis nigricans and infertility.  Psychosocial implications emanating 
from negative self-image can manifest in depression, body dysmorphic disoder and 
eating disorders (Bishop et al, 2009). 
 
The diagnosis of PCOS had previously been difficult due to the diverse phenotypes 
of the patient population.  The American Society for Reproductive Medicine and the 
European Society of Human Reproduction and Embryology have since developed 





 The diagnosis is made on the patient having two of the three criteria  
i) Oligo or anovulation  
ii) Hyperandrogenism – clinical or biochemical 
iii) ultrasound evidence of PCO. 
 
The characteristic hormonal marker of PCOS is hyperandrogenism.  Ovarian 
hyperandrogenaemia occurs as a result of an increase in luteinising hormone 
secretion due to aberrant gonadotropic releasing hormone secretion.  This 
hyperandrogenaemia is further perpetuated by insulin, due to insulin induced 
suppression of hepatic production of sex hormone binding globulin and insulin-like 
growth factor binding protein.  Hyperinsulinaemia or insulin resistance is present in 
20 – 60 per cent of women with PCOS (Azziz et al, 2003). 
 
Insulin resistance and hyperandrogenism have several metabolic sequelae.   
Diabetes Mellitis and impaired glucose tolerance are present in 10 per cent and 35 
per cent of women with PCOS respectively (Legro et al, 1999).  Obesity, as defined 
as a body mass index (BMI) greater than 30 kg/m2, is present in at least 50 per cent 
of women with PCOS (Martinez-Bermejo, 2007).  The combination of 
hyperinsulinaemia, hyperandrogenaemia and obesity predisposes these women to 
cardiovascular disease and the Metabolic Syndrome. NHANES III survey showed 
the prevalence of the Metabolic syndrome in women in the general population to be 
23.7% (Ford et al , 2002). The Metabolic Syndrome is prevalent in 43% of women 




Treatment strategies for women with PCOS are symptomatic. Non pharmacological 
methods include weight loss, cosmetic depilation and lifestyle modifications, such as 
exercise.  Pharmacological agents are used as an adjunct to non pharmacological 
methods.  These are directed at reducing hyperinsulinaemia, hyperandrogenaemia 
and the relevant metabolic sequelae.  Drugs commonly used are oral 
hypoglycaemics eg. Metformin and  antiandrogens such as cyproterone acetate. 
Oral contraceptives are used to regulate menstruation as well as providing an anti 
androgenic effect. 
 
PCOS has been shown to demonstrate phenotypic variability amongst different 
ethnic groups.  The highest reported prevalence of PCOS has been the South Asian 
population that have immigrated to Britain (Wijeyaratne et al, 2002).  These South 
Asian women with PCOS were found to have a greater degree of insulin resistance 
as compared to their Caucasian counterparts.  In addition, these women also display 
features of PCOS at an earlier age. 
Mexican American women have also been shown to have higher prevalence of 
insulin resistance than White, American women (Kauffman, 2002).   There is also 
ethnic variation in the presenting complaints and quality of life in women with PCOS 
(Schmid,2004; Hashimoto,2003) 
 
 Ethnic differences in the prevalence of PCOS in Black women have not been well 
explored. Knochenhauer et al (1998) in their study of Black and White women of 
reproductive age found no significant difference in the prevalence of PCOS between 
both the race groups.  This study, however, did not include the metabolic profile of 
these women.  The severity of PCOS symptoms, demographics and hormonal 
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profiles of local South African women with PCOS has as yet not been described.  
Studies done locally have predominantly focussed on alternate treatment methods.  
In this study we aim to ascertain the phenotypic and biochemical profile of local 
women with PCOS. This study will outline the profile of local Black women and local 
Indian women with PCOS, and in addition assess the prevalence of 





















Polycystic Ovarian Syndrome (PCOS) is an endocrine disorder that affects an 
estimated 5% of all women in the reproductive age group 
 (Solomon,1999).  Initially described in the early 1900’s (Hart, 2004), the disorder 
has evolved into a multifaceted disease pathology that has proved over the years to 
be a diagnostic conundrum, due to its variety of symptoms.  The Rotterdam Criteria 
as suggested at the ASRM/ESHRE consensus meeting, has thus far refined the 
diagnosis of PCOS (Rotterdam ESHRE/ASRM- Sponsored PCOS consensus 
workshop, 2003). 
 
Women with PCOS may present with several symptoms such as: 
 features of hyperandrogenism (alopecia, acne, hirsuitism), 
 menstrual disturbances ( oligo/amenorrhea or dysfunctional uterine bleeding), 
infertility and obesity (Michelmore et al, 1999).  The serum biochemistry, in these 
women, may display abnormalities such as hyperandrogenaemia, an imbalance in 
the normal relationship of the gonadotrophic hormones (follicule stimulating hormone 
and lutenising hormone), hyperinsulinaemia, as well as a hyperlipidaemia 
(Michelmore et al, 1999). 
 
PCOS has serious metabolic implications.   Women with PCOS have a 
predisposition to non insulin dependant diabetes mellitus due to insulin resistance 
and resultant impaired glucose homeostasis (Aganovic, 1996).  These women are at 
greater risk for developing cardiovascular complications and dyslipidaemias 
(Christian et al, 2003) and also have a greater predisposition to develop the 




The variety of clinical presentations in PCOS, lends itself to several treatment 
modalities for these women. These include the oral contraceptive pill, insulin 
sensitizers, anti-androgens as well as non-pharmacological methods such as 
bariatric surgery, diets and lifestyle modifications (Escobar-Morreale , 2008).  In 
women with PCOS, a comparison of lifestyle modification, to medical options such 
as clomiphene citrate and metformin has shown that lifestyle modifications are more 
effective in improving metabolic parameters, with a 20% success compared to 12 



















2. 1  HISTORY OF PCOS 
PCOS was first described by Doctors’ Irving Stein and Michael Leventhal in the early 
1930s.  They reported their findings in 1935 in the American Journal of Obstetrics 
and Gynecology (Balen, 2003).   They had described seven women that presented 
to them with amenorrhea and infertility.  They determined that these women had 
enlarged ovaries with cysts.  Surgical intervention was carried out in the belief that 
removal of these cysts would remove the obstructive effect of these cysts on these 
ovaries.  Post operatively these women had resumption of their menses and five 
achieved conception.  On a follow up report, in 1945, obesity and male type hair 
distribution were added to their growing list of women’s symptoms. 
 
It was not until the 1970’s that further progress was made with the introduction of 
gonadrotropin releasing hormones and oral contraceptive pills in the management of 
PCOS.  This was due to Solomon Berson and Rosalyn Yalow’s 1967 development of 
radioimmunoassay (Rebar, 1976). The initial assays were done with insulin and later 
technology was extrapolated to measure hormonal levels of gonadotropin releasing 
hormones.  The biochemical abnormalities of PCOS were then identified.  Oral 
contraceptives were then utilized to combat these anomalies. 
 
Hyperandrogenism, infertility and methods to overcome these problems were 
extensively researched in the 1980’s.  The clinical features of hyperandrogenism 
were expanded to include acne, skin tags and male pattern balding.  
Pharmacotherapy directed at these features included the use of prednisone, 
ketoconazole, cyproterone acetate, spironolactone, flutamide, and finasteride.  
Infertility treatments aimed at ovulation induction with the use of clomiphene citrate 
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as first line therapy.  Clomiphene citrate is thought to inhibit the negative feedback 
mechanism and results in increased follicle stimulating hormone.   Surgical 
intervention by way of ovarian surgery is recommended if ovulation induction is 
unsuccessful.   The most common technique presently used is ovarian drilling.   
Ovarian surgery should be used in conjunction with clomiphene citrate if ovulation 
does not occur within 12 weeks of ovarian drilling (Bayram, 2004).  Other techniques 
employed are the assisted reproduction techniques such as in vitro fertilization. The 
success rate of in vitro fertilization, in women with PCOS, ranges from 5% – 24% 
(Lintsen et al, 2010). 
 
Pregnancy in women with PCOS is associated with an increased incidence of 
gestational diabetes, gestational hypertension and pre eclampsia (Homburg, 2006).  
This can be attributed to underlying insulin resistance and obesity.  It is therefore 
recommended that these patients be counseled and achieve a BMI less than 30 prior 
to commencing fertility treatments (Balen et al, 2006).  
 
The role of insulin resistance and the metabolic milieu of PCOS were explored 
during the 1990’s and the first decade of the 2000’s.  Metabolic concerns in women 
with PCOS are confounded by obesity which was recognised as one of the initial 
signs of PCOS. This remains one of the major setbacks in the treatment of women 










2.2  Aetiology 
The aetiology of PCOS is largely unknown. Recent advances suggest that PCOS 
may have a genetic component (Franks et al, 1997). In addition, it is also postulated 
that exposure to androgens during intrauterine fetal development contributes to the 
phenotypic expression of PCOS (Xita et al, 2002). 
 
Androgen exposure, in utero, has been documented to cause a diminished effect of 
the GnRH negative feedback mechanism, with resultant neural reprogramming 
(Sullivan et al, 2004).  Experiments done in rats showed that the concentration of 
androgens during early development was central to the hypothalamus programmed 
release of gonadotophic hormones (Barraclough et al, 1961).  These female rats 
later went on to develop anovulatory sterility and polycystic ovaries.  Additional 
studies done in sheep, showed that androgen exposure in utero, resulted in a 
decreased sensitivity of the gonadotrophin –steroid hormone feedback mechanism 
(Padmanabhan et al, 1998).  This decreased efficiency of the feedback mechanism 
resulted in there being an increased LH secretion coupled with aberrant ovarian 
follicular development.  The neural impairment of this pathway was also postulated 
to be as a result of excessive in utero androgen exposure . 
 
Studies done in Rhesus monkeys showed that females exposed, in utero, to 
androgen levels similar to their male counterparts, went on to develop, in later life, 
the clinical and biochemical features of PCOS that are exhibited in adult women 
(Eisner et al, 2002).  These female monkeys also displayed menstrual irregularities 
and ovulatory dysfunction (Abbott et al, 1998).   The menstrual and ovulatory 
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dysfunction was more severe in the female monkeys with increased body mass 
indices, suggesting a hyperinsulinaemic component. 
Metabolic abnormalities described in these monkeys also included aberrant 
secretion and action of insulin – glucose homeostasis and an abnormal distribution 
of adipose tissue.  This included an increase in visceral fat.  These are similar 
characteristics experienced by adult women with PCOS.  
 
Genetic association studies have identified suggested maternal androgens as a 
source of increased androgens that the fetus is exposed to.  The fetus is normally 
protected from maternal androgens by placental aromatases and high amounts of 
sex hormone binding globulin.  In pregnant women with PCOS the efficacy of this 
protective system is reduced by other factors such as hyperinsulinaemia (Sir-
Petermann et al, 2002).  Maternal hyperinsulinaemia also can lead to excessive 
placental HCG production resulting in fetal ovarian hyperplasia and resultant 
hyperandrogenism (Barbieri et al,1986). 
 
Ovarian hyperandrogenism is characteristic of PCOS (Legro et al, 1998).  The 
enzymatic abnormalities are an increased functional activity of cytochrome P450, 3-
beta-hydroxysteroid dehydrogenase and intracellular protein kinases.  These are 
essential for normal ovarian theca cell steroidogenesis.  Several genes have been 
implicated in the pathogenesis of PCOS.  Genes involved in serine phosphorylation  
that may have a contributory role in the development of PCOS and its sequelae are 
the genes regulating the cytochrome P450 C17 alpha enzyme, aldehyde 
dehydrogenase-6 and the CYP11 alpha and CYP17 genes, involved in theca cell 
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steroidogenesis.  To date, however, no conclusive  evidence has thus far 
demonstrated a direct genetic cause for PCOS (Escobar-Morreale, 2005). 
  
Another postulated mechanism for the development of PCOS in hyperandrogenised 
females, is the activin-follistatin-inhibin pathway.  Follistatin is a binding protein of 
activin.  It neutralises the biological activity of activin.  Activin and follistatin can be 
found in the pancreas, adrenal cortex and ovary.  In the ovary, activin enhances the 
development of ovarian follicles, inhibits the production of ovarian androgens by the 
theca cells, increases pituitary FSH release and beta cell insulin secretion (Mather et 
al, 1997).  Follistatin has the opposite effect. The inhibins are comprised of an alpha 
and beta subunit.  They play a role in the in FSH suppression during  the late 
follicular phase  and luteal phase of the menstrual cycle.  Anovulatory  PCOS women 
have decreased levels of inhibin B and lack the pulsatile secretory pattern. Serum 
concentrations of inihibin A are also decreased in anovulatory women with PCOS ( 
Segal, 2010).  Animal studies have also shown that hyperandrogenised females 
expressed increased levels of follistatin and decreased levels of activin beta B 
mRNA (Norman et al, 2001).  This is however thought to have a modest contribution 










2.3  Pathogenesis 
 
The pathogenesis of PCOS is multifactoral.  It is a combination of neuroendocrine, 
ovarian and metabolic mechanisms that lead to an overall propagation of its varied 
presentations and sequelae. 
 
Neuroendocrine mechanism 
Hypothalamic - pituitary - ovarian dysfunction is a key factor in the pathophysiology 
of PCOS.  There is an increased LH secretion from the pituitary. This is a heightened 
response to the GnRH negative feedback mechanism, in response to the 
concentration of the circulating steroid hormones. An increased circulating LH 
delivered to the ovaries, results in an increased stimulation of the theca cells, leading 
to an increased androgen production (Burger et al, 1985). 
 
Ovarian Dysfunction 
 For normal ovarian steroidogenesis, it is essential that there is trophic regulation of 
steroid hormone secretion.   This is dependent on various peptides, such as the 
Insulin- like Growth Factor (IGF) and Insulin-like growth factor binding protein, and is 
responsible for cytochrome P450 C17alpha gene expression.  Women with PCOS 
have low serum levels of Insulin-like growth factor binding protein (Homburg , 1992). 
The resultant deficiency causes impairment in steroid hormone secretion with 
eventual excess of ovarian androgen production (Franks et al,1999). 
 
Intraovarian androgen production is a normal physiological phenomenon that is 
essential for ovarian follicular development.   An excess of androgens, leads to poor 
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follicular development and eventually follicular atresia.  This results in anovulation, 
oligo/amenorrhea, dysfunctional uterine bleeding and infertility. 
 
Insulin resistance 
Some women with PCOS have hyperinsulinaemia.  Insulin levels seemed to 
correlate with androgen levels, suggesting the probable involvement of insulin in the 
pathogenesis of PCOS (Burghen et al, 1980).    
 
Peripheral insulin resistance increases pancreatic beta-cell secretion of insulin.  In 
normal circumstances this relationship is constant to maintain euglycaemia.  In 
women with PCOS, there is an abnormal relationship of this homeostasis, compared 
to weight matched controls (Dunaif et al, 1996).  Evidence of pancreatic beta – cell 
dysfunction has been demonstrated by studies using oscillatory glucose infusions 
and analysing insulin responses in women with PCOS (Erhmann et al, 1995). 
 
The mechanisms for insulin contributing to PCOS are several: 
 Insulin at the level of the pituitary increases serum LH concentration by two 
mechanisms. The first is an increase in the amount of LH secreted by the pituitary 
and the second is by increasing the frequency of LH pulses.  Peripherally, insulin 
acts on the liver by increasing glucose uptake and storage.  High levels of insulin 
suppress hepatic secretion of Insulin like Growth Factor Binding Protein (IGFBP)  
with resultant hyperinsulinaemia. Insulin also decreases the concentration of sex 
hormone binding globulin (SHBG) by inducing hepatic suppression of its production.  




A normal relationship of insulin to IGF is essential for normal steroidogenesis in the 
ovary.  In PCOS, there is an imbalance of this relationship. This leads to inhibition of 
normal ovarian steroidogenesis. In addition, the excessive circulating LH then acts 
on the ovarian theca cells and causes them to undergo follicular atresia. This results 
in anovulation and an increase in intraovarian androgen and later 
hyperandrogenaemia.  
 
The prevalence of abnormal glucose tolerance tests in these women is 45% (Legro 
et al, 2005). This insulin resistance and resultant abnormal glucose tolerance, 
including Type II Diabetes Mellitus, associated with PCOS, is independent of body 
weight (Barcellos et al, 2007).   
 
Obesity and Hyperlipidaemia 
Approximately fifty per cent of women with PCOS are obese (Gambineri, 2002). This 
obesity is predominantly central.  Central obesity is due to an increase in visceral fat.   
 
The adipose tissue in central obesity is more metabolically active and contributes 
toward hyperglycaemia, via the release of free fatty acids from adipocytes. This in 
turn leads to a decrease in glucose uptake by skeletal muscle and the liver, resulting 
in increased circulating glucose. Hyperinsulinaemia in obesity also occurs as a result 
of impaired hepatic insulin sensitivity and an increase in hepatic glucose production 
(Boden et al, 1997). 
 
Women with PCOS are prone to hyperlipidaemia. The predominant dyslipidaemia is 
a higher serum triglyceride level, lower HDL level, a higher LDL/HDL ratio and an 
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increase in LDL levels.  PCOS women therefore have a prolonged exposure to a 
higher level of circulating cholesterol than normal women and have an increased 
prevalence of atherosclerosis (Talbott et al, 2006; Christian et al, 2003).   In addition, 
compared with their age related counterparts, women with PCOS have an increased 

























The syndrome has a wide array of phenotypic variables, which, for some time has 
led to controversy regarding its diagnosis. Symptoms include oligo/amenorrhea, 
infertility, hirsuitism, acne and obesity.  
 
The European Society for Human Reproduction and Embryology and the American 
Society for Reproductive Medicine (ESHRE / ASRM) proposed the following criteria 
for the diagnosis of PCOS (Rotterdam Criteria).  These criteria includes two out of 
three of the following : 
1) oligo/anovulation  
2) clinical or biochemical markers of  hyperandrogenism                      
3) ultrasonographic evidence of polycystic ovaries.  
In addition the criteria excludes any medical disorder that causes oligo/amenorrhea 
and hyperandrogenism 
 
Medical disorders that can present with similar symptoms are Congenital Adrenal 
Hyperplasia (CAH) as well as Cushing’s syndrome.  CAH can be excluded by 
biochemically determining the 17α OHP levels. Cushing’s syndrome, however, 
requires a careful history taking, examination and biochemical testing. The features 
that suggest Cushing’s syndrome are facial plethora, rounded facies, violaceous 
striae, thin skin, bruising and proximal muscle weakness. In addition, in younger 
patients they can present with growth arrest and primary amenorrhea.  A 





This is suggestive by a history of oligo/ amenorrhea, and confirmed by the absence 
of the appropriate biochemical hormonal response to ovulation. A raised LH to FSH 
ratio of greater than 1 is also suggestive of PCOS (Hsu et al, 2009). 
 
2.4.2 Hyperandrogenism 
Clinical markers of hyperandrogenism include the presence of acne and hirsuitism.  
Hirsuitism is classified using the Modified Ferrimen Gallwey Score. A score greater 
than 8 is suggestive of hyperandrogenism, however this is subject to ethnicity. 
 
Biochemical markers are that of raised androgens. This includes raised serum 
testosterone, Dehydroepiandrosterone-sulfate (DHEAS), 17 ά Hydroxyprogesterone 
(17 ά OHP) and Androstenedione. 
  
2.4.3 Ultrasound Features   
These features are: 
i)  an increased ovarian volume (greater than 10 cm3) – on transvaginal scan 
ii)  8- 12 peripheral cysts follicles of between 2 -10mm size 
iii) increased echogenicity of ovarian stroma 
 
The above features should be demonstrated on an ultrasound scan done during 
ovarian inactivity, preferably during day 2-5 of the menstrual cycle. Unilateral 





2.5 PCOS and the Metabolic Syndrome 
The National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) 
guidelines define the Metabolic Syndrome as the presence of three or more of the 
following criteria: 
a) waist circumference in females ≥ 88cm 
b) fasting serum glucose ≥110mg/dl  (6.11mmol/l) 
c) fasting serum triglycerides ≥ 150mg/dl (1.7mmol/l) 
d) serum HDL cholesterol ≤ 50mg/dl (1.3mmol/l) 
e) blood pressure ≥ 130/85 mmHg 
 
Approximately 43% of women with PCOS have the Metabolic Syndrome 
(Apridonidze et al, 2004). This is in comparison with 6 and 15% in the 20-29 and 30-
39 year age group, in women without PCOS, respectively (NHANES III).  The 
Metabolic Syndrome as well as PCOS share a common thread of central obesity, 
hyperinsulinaemia and hyperlipidaemia. This triad of metabolic derangements play a 
pivotal role in the evolution of serious cardiovascular morbidity (Goode et al, 1998). 
 
The most frequent abnormalities detected in women who have both the Metabolic 
Syndrome and PCOS are: 
 low HDL in 68% of women 
 raised body mass index in 67% of women 
 raised blood pressure in 45 % of women 
 hypertriglyceridaemia in 35% of women 
 increased fasting plasma glucose  in 4% of women  ( Wild et al,1985) 
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These abnormalities are also risk factors for cardiovascular disease and Diabetes 
Mellitus type 2 and are more prevalent in women with PCOS than a weight matched 
control (Legro et al, 2002).  The exact mechanism of cardiovascular disease is not 
as yet clearly defined, however insulin resistance seems to be the main contributory 
factor. Studies done, using imaging and echocardiography, suggest that there might 
be both a structural and functional abnormality of the cardiovascular system in 
women with PCOS.  These abnormalities include endothelial dysfunction and arterial 
stiffness (Cussons et al, 2006). 
 
The metabolic dysfunction results in an increased cardiovascular morbidity in women 
with PCOS.  Dahlgren et al (1992) studied the impact of cardiovascular disease on 
women with PCOS. The independent risk factors analysed were age, hypertension, 
diabetes mellitus, central obesity measured as increased waist to hip circumference 
ratio and serum triglyceride concentration.  Women with PCOS were found to have 















Treatment of women with PCOS is individualised and based on women’s symptoms 
and needs.  
 
LIFESTYLE 
Clinically, obese women with PCOS have an increased BMI and waist to hip ratio. 
An increased waist to hip ratio is a greater predictor of cardiovascular disease than 
BMI (Noble R, 2001).  Lifestyle modification and weight loss is the cornerstone of 
therapy for these obese women with PCOS.  Dietary modification and strict calorie 
restricted diet is essential to aid exercise to achieve weight reduction. Weight 
reduction, per se, improves all effects of PCOS. In addition activities such as 
cigarette smoking should be curtailed in an effort to reduce the cardiovascular effects 
of PCOS. 
 
The use of statin therapy for women with PCOS has been experimental.  To date 
there has been no evidence that the use of statins improve menstrual regularity, 
insulin resistance, hirsuitism or acne.  Statins, however, have been shown to 
decrease lipid and testosterone levels (Raval et al, 2011). 
 
Surgical intervention such as bariatric surgery is, of late, a treatment modality that is 
available for the morbidly obese (Escobar- Morreale, 2005). Further research into 





REGULATION OF MENSES 
Oilgo/ amenorrhea as well as dysfunctional uterine bleeding are amongst the key 
features of PCOS, and have a negative psycho-social implication for these women. 
 
Non-pharmacological methods, incorporating lifestyle modifications and weight loss 
may benefit ovarian function and menstruation (Kiddy et al, 1992). 
 
The combined oral contraceptive has been effective in regulating menses. However, 
in women with PCOS and the Metabolic Syndrome, judicious use of the oral 
contraceptive pill, is recommended due to the increased cardiovascular risk for both 
conditions. 
 
Regular menstruation, as a result of improved cyclical ovarian function, has followed 
surgical interventions such as wedge resection and ovarian drilling. 
 
INSULIN RESISTANCE 
Insulin resistance is involved in the pathogenesis of PCOS.  An essential strategy to 
reduce insulin resistance is weight loss and exercise. 
Pharmacotherapy is used as an adjunct to these lifestyle modifications. 
 
The use of insulin-sensitizing drugs such as metformin and thiazolidinediones have 
been suggested as one of pharmacological treatment strategies for women with 
PCOS.  These drugs are used as they exhibit both a metabolic function and an 




Metformin is a biguanide and it reduces insulin resistance (Pirwany et al,1999).  
Insulin sensitising agents also increase circulating levels of SHBG thus lowering 
levels of androgens and this has been shown to improve follicular maturation, 
ovulation and eventual menstruation in PCOS women (Costello et al, 2003).  The 
reduction in androgens also improves hirsuitism and acne. 
 
HIRSUITISM and ACNE 
Hirsuitism and acne occur as a result of hyperandrogenism. There are 2 modalities 
of treatment, the first being topical or mechanical methods and the latter addressing 
the hyperandrogenaemia. 
Mechanical methods of managing hirsuitism involve shaving, application of wax, 
depilatory creams, electrolysis and laser photothermolysis. Electrolysis and laser 
photothermolysis are the most effective but these methods are not permanent 
(Clayton et al, 2005).  Topical preparations for acne include retinoids, antibiotics and 
antibacterial creams. 
 
Oral contraceptives have been used to increase circulating levels of SHBG, thus 
decreasing the levels of free androgens, however this mechanism has only shown to 
be successful in a limited number of women (Wiegratz et al, 2003).   Metformin 
targeting insulin resistance, has demonstrated  an even lower ability to target 
hirsuitism and acne in women with PCOS (Harborne et al, 2003).  Spironolactone, an 
aldosterone antagonist, and a competitive antagonist for the testosterone receptor, 
reduces hirsuitism by up to fifty per cent (Crosby et al, 1991) when used alone, and 
up to seventy five per cent when used in combination with an oral contraceptive 
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(Erenus et al ,1996). Another anti - androgenic agent that has been used is 
cyproterone acetate.  It is usually used in combination with an oral contraceptive pill. 
 
INFERTILITY 
Lifestyle modification and weight loss alone positively influence fertility (Moran et al, 
2003).   
The addition of pharmacological agents acts as an adjunct to lifestyle modification 
and weight loss.  Ovulation induction with clomiphene citrate either alone or in 
conjunction with metformin has been used.  Dosages used in PCOS have to be 
adjusted to body mass index for a greater efficacy (Shepard et al,1979). 
 
The ideal therapy for infertility treatment of women with PCOS has to date been 
controversial.  Various therapies have been considered viz. metformin, clomiphene 
citrate and a combination therapy of metformin and clomiphene citrate. 
Metformin has not been found to increase fertility rates when used as an adjunct to 
assisted reproductive techniques (Tso et al, 2009).  Metformin however, improved 
pregnancy outcomes of women with PCOS (Glueck et al, 2001). Clomiphene Citrate 
has been found to be more effective in non-obese women with PCOS, and may be 
recommended as the first line agent (Legro et al, 2001; Zain et al 2009).  Meta-
analysis of these therapies, however, has not been able to demonstrate superiority 
of any of these therapies over the other (Palomba et al 2009).  
 
Ovarian drilling, either alone or in conjunction with an ovulation inducer has been 




None of the different fertility treatment options have not demonstrated an increased 































Case files of women attending the Gynae-Endocrinology and Gynae – Infertility 
outpatient clinics were retrieved from the IALCH medicom database. 
 
Diagnosis of PCOS was made according to the Rotterdam Criteria as proposed by 
The European Society for Human Reproduction and Embryology and the American 
Society for Reproductive Medicine (ESHRE / ASRM). This diagnosis was made on 
two out of three criteria : 
 oligo/anovulation  
 Clinical or biochemical markers of  hyperandrogenism                      
 ultrasonographic evidence of polycystic ovaries 
 In addition the diagnosis was made after the exclusion of other medical disorders 
that cause oligo/amenorrhea and hyperandrogenism 
 
An audit of all women attending the Gynaecology Endocrine and Infertility clinics 
over the period June 2005 to June 2009 was carried out 
 
Demographic data collected included age, race group and presenting complaint/s.  
Clinical data included signs of hirsuitism, acne, insulin resistance, blood pressure, 
height, weight, and waist and hip measurements.  Body mass index and waist hip 




All women were subjected to serum biochemistry that included FSH, LH, Estradiol, 
Prolactin, TSH, T4, DHEAS, fasting Insulin, Androstenedione, 17 OHP, 
Testosterone.  
 
All women underwent a screening glucose tolerance test.  This included the 
ingestion of 75g of glucose and a serum glucose being measured 2 hours later. A 
value of greater than 6.0 mm/l was considered to be abnormal.  Any woman with 
abnormal screening glucose tests were then subjected to a full oral glucose 
tolerance test.  
 
The lipid profiles of these subjects were tested after a fast. This profile included the 
measurement of HDL, LDL, total cholesterol as well as triglyceride levels.   
 
Transvaginal ultrasounds were performed on all women. All ultrasound examinations 
were performed by a qualified ultrasonographer, employed by the hospital. The 
diagnosis of polycystic ovaries on ultrasound was made in accordance with the 
American Society for Reproductive Medicine (ESHRE / ASRM) criteria for the 
ultrasonographic features of PCOS.  These include: 
i) an increased ovarian volume (greater than 10 cm3) – transvaginal scan 
ii)  8- 12 peripheral follicles/cysts 








The hormonal profiles were analysed using the Advia Centaur. Trophic hormones 
such as TSH, FSH, LH, Prolactin, as well as Testosterone and Insulin were analysed 
using chemiluminescent immunoassay.   DHEAS and Androstenedione were 
analysed via radio immunoassay – manual method.  Glucose was analysed using 
the enzymatic method using hexokinase. Total Cholesterol and Trigylceride levels 
were analysed using end point enzymatic assay. HDL was analysed using 2 point 
kinetic enzymatic assay.  The intra and interassay coefficients of variances for 
prolactin was 9.9% and 12% ; for FSH 15.3% and  9.2% ; for LH 28.5% and 11% ;  
for TSH 11.2% and 9.5% ; for free thyroxine 11.5% and 7.3% ; for testosterone 
13.6%  and 14.4%; for DHEAS 9.8% and 8.0%; for 17 α OHP 6.7% and 7.1%; for 
androstenedione 11.1 and 9.8%; for estradiol 12.1% and 8.2% respectively.  The 
intra and interassay coefficients of variances for  the metabolic profile of these 
patients were as follows: for insulin 10.2%   and 7.9%; for glucose 6.9% and 3.4%; 
for triglycerides 5.6% and 2.9%; for cholesterol 5.9% and 1.2% and for HDL 8.4% 
and 9.9% respectively. 
 
Statistical analysis was done with the aid of a statistician. The software package 
used was the SPSS system. Demographic and historic dichotomous variables were 
compared by x2 analysis using the Pearson test as well as Fisher’s exact test. 







4.  RESULTS 
The case files of 480 women from the period June 2005 to June 2009 were 
analysed.  Of these 480 files, 110 had the diagnosis of PCOS according to the 
Rotterdam Criteria (Rotterdam ESHRE/ASRM- Sponsored PCOS consensus 
workshop, 2003) and were included in this study.  There were 87 Indian women, 16 
Black women, 5 Coloured women and 2 White women with PCOS.  The Coloured 
and White women were excluded from further analysis due to the small number of 
women. The Indian and Black women were analysed separately and compared to 
each other.  A p-value of <0.05 was accepted as significant. 
 
Demographic data is displayed in Table 1.  The mean age of PCOS women 
attending IALCH was 27 years and no statistical differences between the ages of the 
Indian and Black population was found.  Eighty nine per cent of women in this study 
had an increased body mass index (BMI >25).  The majority of these women (69.7%) 
were classified obese (BMI >30), and 19.3 % were overweight (BMI 26-30).  There 
was no significant difference in the body mass indices between the Indian and Black 
groups. 










AGE  (years) 27.80          (4.78) 27.00                (6.69) 0.54 
HEIGHT (m)   1.58          (0.06)   1.59                (0.06) 0.47 
WEIGHT (kg) 81.44        (19.24) 77.78              (19.41) 0.49 
BMI (kg/m2) 32.10         ( 7.51) 30.50                (6.46) 0.44 
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Table 2 displays the frequency of the presenting complaints of women with PCOS.  
Women with PCOS presented with oligo/amenorrhea, dysfunctional uterine bleeding, 
acne, hirsuitism and infertility.  Infertlity was defined as a failure to conceive after a 
year of trying, in the absence of contraception. 
 
The most frequent presenting complaint, menstrual irregularities, was found in 55 
women (50%).  Menstrual irregularities were subdivided into oligo/amenorrhea and 
dysfunctional uterine bleeding.  Infertility (44.5%) was the second commonest reason 
to warrant medical assistance. Hyperandrogenic symptoms were amongst the main 
complaints in 8.2% of these women. 
 
Table 2. Presenting complaints of all* women with PCOS   (n=110) 
   
PRESENTING COMPLAINTS  n % 
   
OLIGO/AMENORRHEA 35 32 
   
DYSFUNCTIONAL UTERINE BLEEDING 17 15.4 
   
ACNE/HIRSUITISM  6 5.5 
   
INFERTILITY 49 44.5 
   
OLIGO/AMENORRHEA + ACNE/HIRSUITISM  3 2.8 
   
   
 
  
   







Table 3 shows the presenting complaints in Indian and Black women with PCOS.  
There were no statistical differences between Indian and Black women regarding 
oligo/amenorrhea, dysfunctional uterine bleeding, acne/ hirsuitism as well as 
infertility.   
 
  

















































































Table 4 shows the biochemical parameters of Indian and Black women with PCOS.  
The biochemical parameters analysed were thyroid profiles, estradiol, levels, 
androgen profiles as well as prolactin levels. Individual biochemical parameters 
amongst Indian and Black women with PCOS revealed no statistically significant 
differences between the groups. 
Table 4. Hormone profile {mean and (SD)} of African and Indian women with    PCOS 
 INDIAN BLACK          p-value  
FSH (mIU/mL)  4.97             (2.0) 
 
5.32             (2.44) 0.53 
 
LH   (mIU/mL)  8.94           (5.63) 
 




PRL (mIU/ml) 347.1        (392.6) 
 




TSH (mIU/L) 6.85          (34.64) 
 
1.87             (0.98) 0.58 
 
T4 (pmol/L) 14.92          (2.87) 15.84           (2.43) 0.39 
 
ESTRADIOL (pmol/L) 276.85    (430.74) 372.20     (268.19)               0.45 
TESTOSTERONE 
(nmol/L) 




  14.2            (7.3)   9.00            (3.81) 0.53 
 
17ά OHP (mg/L)   4.71           (3.30) 5.32             (2.30) 0.61 
 
DHEAS (nmol/L)   6.22           (4.01) 7.92             (6.43)               0.23 






Table 5 displays the biochemical profiles of women with PCOS.  In our study 
population, we found an increased LH to FSH ratio in 78.2% of women. Assessment 
of the androgenic milieu included total serum testosterone, DHEAS, 
androstenedione  and 17ά OHP.  Hyperandrogenaemia was defined as an elevated 
serum testosterone and/or androstenedione and /or DHEAS. Thirty four percent of 
women studied were found to have raised androgen levels.  Fasting 
hyperinsulinaemia (>25 uIU/L)  was found in half the population of women studied 
(50.9%).  An increased fasting serum glucose (>6 mmol/L) of 23.9 % and 
hyperlipidaemia of 11.3% was found in women with PCOS. 
 
Table 5. Biochemical Profile of all women with PCOS (n=110) 
                     n                                % 
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A comparative analysis of these parameters between Indian and Black women 
showed no statistical differences, as demonstrated in Table 6.  There is, however, a 
trend toward there being more fasting hyperglycaemia amongst Indian women as 
compared to Black women with PCOS. 
 
 






        p-value 
                             
RAISED LH:FSH 
  
66       (75.9%) 
 






26       (30.2%) 
 






48        (55.2%) 
 






25        (29.1%) 
 




RAISED CHOLESTEROL 12        (14.3%)    0             (0%) 0.12 














The prevalence of lipid abnormalities is shown in Table 7.  Thirty women had lipid 
abnormalities.  Raised triglycerides and low levels of HDL were found to be more 
frequent manifestations in our study population. 
 
Table 7.  Prevalence of Lipid abnormalities in all women with PCOS (n=110) 
   n   % 




 12   11 
RAISED TRIGLYCERIDES 
(>2.26mmol/L) 
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1.8 
LOW HDL ( <1.6mmol/L)   10    9 
RAISED LDL (>4.1mmol/L)   8    7 
 
Comparative analysis of the lipid profiles between the Indian and Black women 
showed no statistical difference (Table 8). 
Table 8. Comparative Lipid profile (Mean and SD) of all women with PCOS 




4.96            (1.07) 
 






1.76            (1.05) 
 






1.32            (0.23) 
 




LDL 2.84            (0.92) 3.58                (3.44) 0.12 
    




Table 9 shows women with an abnormal screening glucose tolerance test.  In the 
Indian population, 13 (14.9%) were found to have Diabetes Mellitus, and 9 (10.3%) 
had an impaired glucose tolerance test. In the Black population only 1 patient had 
impaired glucose tolerance.  There were no Black women with Diabetes Mellitus. 
 



















  9            (10.3%) 
 




DIABETES MELLITUS 13            (14.9%)  0      0.21 
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5.  DISCUSSION 
 
The objectives of this study were three-fold. The first objective was to establish the 
profile regarding the clinical presentation and biochemical parameters of women with 
PCOS attending IALCH.  The second objective was to assess the frequency of 
hyperlipidaemia and insulin resistance in these women, and thirdly to compare these 
profiles in Indian and Black women with PCOS. 
 
The most frequent presenting complaint was menstrual irregularity in 49.5% of 
women. Forty four point five percent of women presented with infertility and 8.2% 
presented with hyperandrogenism.   The clinical profiles of our women did not differ 
from previous studies (Shi et al, 2007).   The majority of our women were found to be 
obese (69.7%).  This is higher than that found in other PCOS populations where the 
prevalence of obesity is between 30 –35% (Li et al, 2005; Li et al, 2007).  Features of 
hyperandrogenism were present in 8.2% of women.  The prevalence on insulin 
resistance in our study population was 50.9%.  Twelve per cent of these women also 
had hyperlipidaemia. 
 
The most frequent reasons for women with PCOS seeking medical help were related 
to menstrual irregularities and infertility (Table 2).  The prevalence of these leading 
main complaints are similar to previous studies (Shi et al, 2007; Vutyavanich et al, 
2007).  It is interesting to note that only 5-6% of women presented with the primary 
complaint of hyperandrogenism as compared to other studies (Ozdemir, 2010; Li et 
al, 2007).  The possible reason for this might be the social acceptance of excessive 
hair growth in the population studied or the widespread use of depilatory techniques.  
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None of the women with PCOS presented with symptoms of Diabetes Mellitus or 
symptoms of cardiovascular disease being their main complaints. 
Studies reported by Erhmann et al (1999) and Legro et al (2005) showed the 
prevalence of glucose abnormalities in women with PCOS being 45 % and 38.6% 
respectively. The prevalence of type 2 Diabetes Mellitus in these studies was ranged 
from 7.5% to 10% and impaired glucose tolerance from 31.1% to 35%.  In our study, 
the prevalence of Type 2 Diabetes Mellitus was 14.9% and impaired glucose 
tolerance was found in 10.3 % of the Indian women.  Only 1 Black woman in our 
study had impaired glucose tolerance (Table 9).  This is in keeping with previous 
studies which showed that the Indian population in Durban has a higher prevalence 
of Diabetes as compared to the Black population, the prevalence rates being 10% 
and 1.6% in Indians and Blacks respectively (Asmal et al, 1981).  
 
Lipid abnormalities are closely associated with PCOS.  The major serum lipid 
abnormalities described are a reduced HDL, increased triglycerides, elevated LDL 
and a higher LDL – HDL ratio (Wild et al, 1985).  Women with PCOS who have an 
associated lipid abnormality have a greater predisposition to develop cardiovascular 
disease and morbidity (Christian et al, 2003). In local Indian women, the prevalence 
of hyperlipidaemia was 14.3%, in contrast to no Black woman in our study having 
hyperlipidaemia (Table 6).  Despite the majority of the women having normal serum 
cholesterol, atherogenic abnormalities have been found in one-third of women with 
PCOS who have a normal lipid pattern (Berneis et al, 2009). 
 
The presence of insulin resistance, glucose abnormalities, hyperlipidaemia and 
obesity precedes the development of the Metabolic Syndrome.  The prevalence of 
the Metabolic Syndrome in women with PCOS is about 43% (Apridonidze et al, 
38 
 
2004). The most frequent abnormalities detected in women who have both the 
Metabolic Syndrome and PCOS are low HDL, raised body mass index, raised blood 
pressure,   hypertriglyceridaemia and an increased fasting plasma glucose ( Wild et 
al,1985).  In our study population, an increased BMI >25 was found in 89% of 
women. Eighty eight per cent of Indian women had a BMI>25 compared to 81% in 
Black women.  Low HDL was found in 66.7 % of women, raised triglycerides in 79% 
and only 23.9% of women had raised fasting glucose.  This suggests that the 
Metabolic Syndrome may be present in a significant number of local Indian women 
with PCOS. 
 
Ultrasound findings showed that the majority of the local population studied, had 
polycystic ovaries.  Polycystic ovaries on ultrasound, either bilateral or unilateral 
were found in 83% of Indian women and 93.8% of Black women. 
This has clinical significance as the absence of this radiological feature should not 
exclude the diagnosis of PCOS.  Conversely, the presence of polycystic ovaries on 
ultrasound should not be used in isolation to make the diagnosis of PCOS.  The 
prevalence of isolated polycystic ovaries on ultrasound can occur in 25% of normal 
women of reproductive age (Franks et al, 2004). 
 
In terms of public health relevance, our findings suggest that South African women 
with PCOS, have similar presentations and profiles as women with PCOS globally.  
However, in Black women, the most common presenting complaint was infertility and 
not menstrual irregularities and hyperandrogenism (Table 3).  In local Indian women, 
the presence of type 2 Diabetes Mellitus is greater than international rates (Vrbikova, 
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2009). This emphasizes the need for establishing the metabolic parameters in every 
patient with PCOS, and to maintain long term regular follow up of these women. 
 
Our study has found that PCOS is an entity in Black women as well.  It can be 
presumed, that the small number of Black women is a shortcoming of this study.  
However it must be noted that PCOS in Black women has been seldom described in 
the literature (Knochenhauer et al, 1998).  This study highlights the low number of 
Black women seen and indirectly suggests a possible lower prevalence of PCOS in 
the Black population.  This study gives insight into the main presenting complaint 
and biochemical variables in Black women with PCOS. A bigger sample size of 

















6.  RECOMMENDATIONS 
 
Contemporary management of women with PCOS consists of varying investigations 
and treatment modalities.  These investigations target women’s symptoms to aid the 
diagnosis of PCOS.  This approach and the management of a patient with PCOS in 
this manner can completely disregard the metabolic disarrangement experienced by 
these women. 
 
Our results show that metabolic abnormalities in South African women with PCOS 
do exist irrespective of race.  If left untreated, these abnormalities can progress to 
serious cardiovascular morbidity.  It is essential to recognise these women as high 
risk and screen for metabolic disarrangements.  Judicious follow up these for these 
women is recommended to identify and institute early necessary treatment if 
required.   
 
There are as yet, no local treatment protocols for the management of women with 
PCOS. In addition, there are no clear guidelines to screen these women for 
metabolic disorders. Our study shows the prevalence metabolic sequelae  in Black 
and Indian women with PCOS.  We therefore recommend the development of a 









Normal values used by the chemical pathology laboratory at IALCH. 
FSH  
Follicular phase                    2.5 -10.2        mIU/mL 
Midcycle peak                      3.4 -33.4         mIU/mL 
Luteal phase                        1.5 -1.9           mIU/mL 
 
LH 
Follicular phase                    1.9 -12.5        mIU/mL 
Midcycle peak                       8.7 -76.3       mIU/mL 
Luteal phase                         0.5 -16.9       mIU/mL 
 
Prolactin                                121 -619          mIU/ml 
TSH                                       0.27 -4.2        mIU/L 
T4                                         11.5 -22.7       mIU/L 
Estradiol                   
Follicular phase D2              40 -253           pmol/L 
                           D10           231-606          pmol /L 
Midcycle             D13           536-1930        pmol /L 
Luteal phase      D16           121-551           pmol/L 
                           D20            250-719          pmol/L 
                           D26           132-448           pmol/L 
 
Testosterone                        0.5-2.6           nmol/L 
Androstenedione                  1-12.2            nmol/L 
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DHEAS                                 0.9-11.7        nmol/L 
17 OHP                                 0.88 – 12.1  nmol/L 
Fasting insulin                       3-25              uIU/L 
Fasting glucose                     <7.8             mmol/L 
Total Cholesterol                   <6.22           mmol/L  
Triglycerides                          <2.26           mmol/L 
HDL                                        >1.6            mmol/L 
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